Literature DB >> 24563870

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

Encouse B Golden1, Sandra Demaria2, Peter B Schiff1, Abraham Chachoua3, Silvia C Formenti1.   

Abstract

A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclonal anti-CTLA-4 antibody) induced immune-mediated abscopal effects in poorly immunogenic pre-clinical tumor models and metastatic melanoma patients. However, no such reports exist for patients with metastatic lung adenocarcinoma. We report the first abscopal response in a treatment-refractory lung cancer patient treated with radiotherapy and ipilimumab. A post-treatment increase in tumor-infiltrating cytotoxic lymphocytes, tumor regression, and normalization of tumor markers was observed. One year after treatment with concurrent radiotherapy and ipilimumab the patient is without evidence of disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24563870      PMCID: PMC3930458          DOI: 10.1158/2326-6066.CIR-13-0115

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  26 in total

1.  Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.

Authors:  Ryan J Sullivan; Donald P Lawrence; Jennifer A Wargo; Kevin S Oh; R Gilberto Gonzalez; Adriano Piris
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

2.  Immunologic correlates of the abscopal effect in a patient with melanoma.

Authors:  Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

3.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

4.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

5.  Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Authors:  Karsten A Pilones; Noriko Kawashima; Anne Marie Yang; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

6.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 7.  Systemic effects of local radiotherapy.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  Lancet Oncol       Date:  2009-07       Impact factor: 41.316

8.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.

Authors:  Sandra Demaria; Bruce Ng; Mary Louise Devitt; James S Babb; Noriko Kawashima; Leonard Liebes; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

9.  The abscopal effect associated with a systemic anti-melanoma immune response.

Authors:  Emily F Stamell; Jedd D Wolchok; Sacha Gnjatic; Nancy Y Lee; Isaac Brownell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-05       Impact factor: 7.038

10.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Authors:  Maria Grazia Ruocco; Karsten A Pilones; Noriko Kawashima; Michael Cammer; Julie Huang; James S Babb; Mengling Liu; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

View more
  244 in total

Review 1.  Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors:  Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal:  Cancer Discov       Date:  2014-11-13       Impact factor: 39.397

2.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

Authors:  Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-05       Impact factor: 7.038

Review 3.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Authors:  Kobe Reynders; Tim Illidge; Shankar Siva; Joe Y Chang; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2015-03-28       Impact factor: 12.111

Review 4.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

Review 5.  DNA Damage and Repair Biomarkers of Immunotherapy Response.

Authors:  Kent W Mouw; Michael S Goldberg; Panagiotis A Konstantinopoulos; Alan D D'Andrea
Journal:  Cancer Discov       Date:  2017-06-19       Impact factor: 39.397

6.  Harnessing the Immunomodulatory Effects of Radiation in Urinary Bladder Cancer.

Authors:  Waseem Abbas; Vineeta Goel; Arun Verma; Vineet G Gupta; Ranga R Rao
Journal:  Cureus       Date:  2019-02-20

7.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

Authors:  Grit S Herter-Sprie; Shohei Koyama; Houari Korideck; Josephine Hai; Jiehui Deng; Yvonne Y Li; Kevin A Buczkowski; Aaron K Grant; Soumya Ullas; Kevin Rhee; Jillian D Cavanaugh; Neermala Poudel Neupane; Camilla L Christensen; Jan M Herter; G Mike Makrigiorgos; F Stephen Hodi; Gordon J Freeman; Glenn Dranoff; Peter S Hammerman; Alec C Kimmelman; Kwok-Kin Wong
Journal:  JCI Insight       Date:  2016-06-16

Review 8.  Current clinical trials testing combinations of immunotherapy and radiation.

Authors:  Marka Crittenden; Holbrook Kohrt; Ronald Levy; Jennifer Jones; Kevin Camphausen; Adam Dicker; Sandra Demaria; Silvia Formenti
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

Review 9.  Tumor-associated macrophages and anti-tumor therapies: complex links.

Authors:  Cristina Belgiovine; Maurizio D'Incalci; Paola Allavena; Roberta Frapolli
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

Review 10.  Radiotherapy and Immunotherapy Combinations for Lung Cancer.

Authors:  Vishesh Agrawal; Kimberly Thomas Benjamin; Eric C Ko
Journal:  Curr Oncol Rep       Date:  2020-11-19       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.